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Ablation for atrial fibrillation
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Aims It is recommended to keep exposure to ionizing radiation as low as reasonably achievable. The aim of this study was to
determinewhetherfluoroscopy-freemapping andablationusing a standardizedprocedural protocol is feasible inpatients
undergoing pulmonary vein isolation (PVI).
Methods and
results
Sixty consecutive patients were analysed: Thirty consecutive patients undergoing PVI using Carto3 were treated using a
standardized procedural fluoroscopy protocol with X-ray being disabled after transseptal puncture (Group 1) and com-
paredwith a set of previous 30 consecutive patients undergoingPVIwithout a specific recommendation regarding theuse
of fluoroscopy (Group 2). The main outcome measures were the feasibility of fluoroscopy-free mapping and ablation,
total fluoroscopy time, total dose area product (DAP), and procedure time. Sixty patients (age 60+10 years, 73%
male, ejection fraction 0.55+0.09, left atrium 42+ 8 mm) were included. In Group 1, total fluoroscopy time was 4.2
(2.6–5.6) min and mapping and ablation during PVI without using fluoroscopy was feasible in 29 of 30 patients (97%).
In Group 2, total fluoroscopy time was 9.3 (6.4–13.9) min (P, 0.001). Total DAP was 13.2 (6.2–22.2) Gy*cm2 in
Group 1 compared with 17.5 (11.7–29.7) Gy*cm2 in Group 2 (P ¼ 0.036). Total procedure time did not differ
between Groups 1 (133+37 min) and 2 (134+ 37 min, P ¼ 0.884).
Conclusion Performing mapping and ablation guided by an electroanatomic-mapping system during PVI without using fluoroscopy
after transseptal puncture using a standardized procedural protocol is feasible in almost all patients and is associated
with markedly decreased total fluoroscopy duration and DAP.
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Introduction
Interventional treatmentofcardiac arrhythmiasusing catheterablation
is commonly performed under fluoroscopic guidance resulting in ex-
posure to ionizing radiation for patients and physicians.1,2 Although
dataon late adverse effects of radiation in patients undergoing catheter
ablation procedures requiring prolonged fluoroscopy times are
missing, it is known that ionizing radiation has a small, but inherent
risk of future neoplasms.3 The U.S. Nuclear Regulatory Commission
recommends making every reasonable effort to keep exposure to
ionizing radiation as low as reasonably achievable (ALARA), a state-
ment that is endorsed by the major societies of physicians working
in an interventional laboratory.4 Pulmonary vein (PV) isolation (PVI)
has become the mainstay of interventional treatment in patients with
atrial fibrillation.5 The procedure was initially performed mainly
under fluoroscopic guidance, and mean fluoroscopy times of .2 h
were reported even by experienced centres for procedures
performed between 2002 and 2006.6 Various generations of
electroanatomic-mapping (EAM) systems have increased the spatial
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resolution of the available anatomical information and by that consid-
erably decreased the radiation burden of the procedure.7 To fully
benefit from the technological improvement of the EAM systems, it
is recommended that ‘the operators need to develop procedural
workflows to relyonnon-fluoroscopic guidance asmuch aspossible’.8
The aim of this study was to determine whether fluoroscopy-free
mapping and ablation is feasible when using a standardized proced-
ural protocol in patients undergoing PVI using radiofrequency
energy and to compare this approach with procedures performed
without a specific recommendation for the use of fluoroscopy.
Methods
This is a non-randomized comparisonof 60 consecutive patientswith
paroxysmal or persistent AF undergoing PVI (without additional left
atrial lesions). Thirty consecutive patients undergoing PVI were
treated using a standardized procedural fluoroscopy protocol
(Group 1) and compared with a set of previous 30 consecutive
patients undergoing PVI before the standardized fluoroscopy proto-
colwas implemented (Group2). Exclusion criteria for the studywere
a history of any previous left atrial procedure (surgical or percutan-
eous) and documented left atrial tachycardia requiring additional
ablation lines.
Transesophageal echocardiography to ruleout left atrial thrombus
was performed before the procedure. Oral anticoagulation was not
interrupted for theprocedure inpatientsonVitamin-Kantagonistsor
Rivaroxaban. In patients onDabigatran, the dose the night before and
themorning of the procedurewaswithheld. All patients gavewritten
informed consent for participation in a prospective, observational
registry.
Magnetic resonance imaging
Magnetic resonance imaging (MRI) was performed on a 1.5T scanner
(MagnetomAvanto/Espree, Siemens, Germany) equipped with phased
array body coils. A respiratory- and ECG-gated three-dimensional
balanced steady-state free precession sequence was acquired in axial
orientation covering the whole left atrium.
Electrophysiological procedure
Midazolam, Fentanyl, and Propofol were used to perform PVI under
conscious sedation. Intravenousheparinwas used tomaintain an acti-
vated clotting time of 350 s. The sheaths were continuously flushed
with heparinized saline. Intracardiac electrograms and surface elec-
trograms were recorded and displayed at a speed of 100 mm/s.
The endpoint was the elimination of all PV potentials on the variable
20-pole circumferential-mapping catheter. All procedures were
performed in conjunction with a 3D EAM system (Carto3, Biosense
Webster, Diamond Bar, CA, USA) and all patients underwent
pre-procedural MRI for 3D reconstruction of the left atrium.
After obtaining vascular access via the right femoral vein, two long
sheaths (SL1, 8.5F, St. JudeMedical, MN, USA) were placed in the su-
perior venacavaover a J-tip guidewire. The irrigated tip ablation cath-
eter (Navistar Thermocool/SF/SmartTouch, BiosenseWebster)was
placed in the coronary sinus to serve as a reference during transseptal
puncture. Double transseptal puncture was performed in the usual
fashion under radiologic guidance. No PV angiographies were
performed.
Mapping and ablation protocol
In the fluoroscopy-freemapping and ablation group (Group1), fluor-
oscopy was disabled and the operator took off the lead protection
after double transseptal puncture. Fluoroscopy, however, was
allowed to be turned back on at all times during the procedure and
could be used at the operator’s discretion at any time. No additional
imaging technique (e.g. intracardiac or transesophageal echocardiog-
raphy) was used. The workflow enabling fluoroscopy-free mapping
and ablation is as follows.
The ablation catheter positioned in the coronary sinus during
transseptal puncture was then pulled back to the right atrium while
the fast anatomical-mapping (FAM) function of Carto3 was activated
in order to acquire the anatomyof the coronary sinus (Figure 1A). The
left atrial reconstruction of the pre-procedurally acquired MRI was
provisionally positioned based on the previously acquired FAM
map of the coronary sinus in order to have an approximation of
the position of the PVs. The site of the transseptal access was
marked with a ‘sleeve’ during advancing of the mapping catheter
through the transseptal sheath. This tag helped to re-access the left
atrium in case of inadvertent loss of the left atrial access during the
procedure.
In the Carto3 system, the ring electrodes of the ablation catheter
are shown in black as opposed to the standard grey if they are still
within the sheath.Consequently, the endof the sheath is represented
by the transition between the grey and the black visualization of the
proximal electrodes of the mapping catheter (Figure 1B).
The ablation and circumferential-mapping catheter were then
inserted into the left atrium with both catheters connected in
order to visualize their entry into the left atrium (Figure 1B) in real-
time and to observe the intracardiac electrograms, mainly in order
to prevent inadvertent positioning of the circumferential-mapping
catheter in the mitral valve apparatus.
The left atrium was mapped with the variable 20 pole
circumferential-mapping catheter using the FAM feature and
maximal resolution. The left atrial reconstruction from the MRI was
used todefine the anatomyof thePVs (Figure 1C). The circumferential-
What’s new?
† Performing mapping and ablation without using fluoroscopy
after transseptal puncture is feasible in the vast majority of
patients undergoing atrial fibrillation ablation without add-
itional technical equipment such as intracardiac or transeso-
phageal echocardiography.
† Adopting aprocedural protocolwith theaimof avoidingfluoros-
copy after transseptal puncture results in a marked decrease in
fluoroscopy time, radiation dose, and effective dose compared
with pulmonary vein isolation procedures using the same
mapping system but no specific recommendation regarding
fluoroscopy.
† Outcome and complication rates did not differ between the
different approaches.
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mapping catheterwasthen advanced into the left superiorand inferior,
and then into the right superior and inferior PV. The remaining septal,
posterior, superior, and antero-superior structures including the left
atrial appendage were then mapped with the circumferential
mapping catheter. The inferior left atrium (along the coronary sinus
to the inferior septum) and the mitral annulus region were mapped
with the ablation catheter using FAM in order to avoid mapping in
close proximity to the mitral valve apparatus and to avoid inadvertent
loss of left atrial accesswith the circumferential-mapping catheter. The
previously acquired FAMmap of the coronary sinus was used to pre-
define the inferior left atriumandmitral annulus region.Then, the ridge
between the left atrial appendage and the left PVswasmapped inmore
detail using the mapping catheter.
After completing the left atrial map, PVI was achieved by perform-
ing circumferential antral ablation using radiofrequency energy with
the power set to 25–30 W (maximum 40 W) and a maximum tem-
perature of 508C using continuous encircling lesions. Contact force
information, where available, was used during ablation with a target
force of 10 g and an upper limit of 40 g during the entire procedure
(Figure 1D). The level of the catheter tip in relation to the tip of the
sheath was determined by observation of the appearance of the
proximal electrode pair of the ablation catheter (Figure 1B). The pro-
cedural endpoint of the ablation was the elimination of all PV poten-
tials on the 20 pole circumferential-mapping catheter (entrance
block). Pacing maneuvers were used to differentiate far field from
PV potentials.
In Group 2 (standard use of Carto3 with no recommendation
regarding fluoroscopy), transseptal punctures were performed as in
Group 1 under radiologic guidance and fluoroscopy was used as
deemed necessary by the operator during the mapping and ablation
procedure. There was no specific workflow for mapping and ablation
as described above. All analysed patients of the two groups were en-
rolled consecutively after at least 2 years of experience of the opera-
tors with the EAM system Carto3. All complications were classified
according to the HRS/EHAR/ECAS expert consensus statement on
AF ablation.5
Post-ablation management and follow-up
Transthoracic echocardiographywas performed after the procedure
to rule out pericardial effusion. The first doseofDabigatranwas given
A B
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Figure1 Images of theprocess and the features used for fluoroscopy-freemapping and ablationof the left atrium: (A) posterior viewof the FAMof
the coronary sinus (grey)with themanually registered anatomical reconstruction of the left atrium fromMRI (yellow), (B) same posterior view as in
(A) with the FAMof the transseptal puncture: the transition between the black and the grey visualization of the two proximal ring electrodes of the
mapping cathetermarks the exit of the catheter from the sheath and consequently the end of the sheath (dashed line). (C) Left lateral viewof the left
atriumwith theLassocatheter in the left superiorpulmonary vein. (D)Contact force vector and the two-ring catheterprojection as representationof
the distance of the catheter tip from the closest FAMsurface. The closer the catheter is to the surface, the smaller is the difference of the diameter of
the two white rings projected on the grey surface.
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four hours after achieving haemostasis and Vitamin K antagonists and
Rivaroxaban were resumed the night of the procedure.9 Oral antic-
oagulation was continued for at least 3 months. Follow-up consisted
of outpatient clinic visits at 3 and 6 months and then every 6 months
and included a detailed history, physical examination, 12-lead ECG,
24-hHoltermonitoring and a 7-day Holter at 12months. In addition,
patients were seen in case of recurrent symptoms. Episodes of
AF (.30 s) were counted as recurrences. Recurrence rates were
analysed with a post-procedural blanking period of 3 months.
Main outcomemeasures
The primary endpoints of this study were the feasibility of
fluoroscopy-free mapping and ablation (after transseptal puncture),
total fluoroscopy time as a measure of the ‘need’ for fluoroscopy
verification, total dose area product (DAP; defined as the sum of
cine and fluoroscopic acquisition), effective dose (ED), and total pro-
cedure time in the fluoroscopy-free ablation (Group 1) compared
with the control group undergoing PVI with the same EAM system
but no specific recommendation regarding fluoroscopy (Group 2).
Secondary outcome measures were complications, the occur-
rence of radiation dermatitis, acute and 1-year single procedure
success rates of PVI, and procedural details (time needed for
mapping, time needed for ablation, and net RF time).
Statistical analysis
Continuous variables are presented as mean+ 1 standard deviation
or asmedian and interquartile range (IQR) in case of skeweddistribu-
tion. For continuous variables, comparisons were made using
Student’s t-test, or Mann–Whitney U test, as appropriate. Discrete
variables were compared using the Fisher’s exact test. A P-value
of ,0.05 was considered to indicate statistical significance. The
statistical analyses were performed using the SPSS (version 22.0,
SPSS Inc., Chicago, IL, USA) software package.
Results
Study population
A total of 60 patients undergoing PVI were included in the study.
Patients had a mean age of 60+ 10 years, and 44 (73%) were men.
The majority of patients (72%) had standard PV anatomy with 4
PVs, 10 (17%) had a left common ostium, and 7 (11%) had a middle
right PV. There were no differences in patient characteristics
between the groups. Baseline characteristics of the patients are
given in Table 1.
Primary outcomemeasures
Performing themapping and ablation procedurewithout using fluor-
oscopy after the transseptal puncturewas feasible in 29of 30 patients
(97%). In one patient with a very small right inferior PV, 1.9 min of
fluoroscopy was required to position the circumferential-mapping
catheter in the right inferior PV for confirmation of PVI after ablation.
Total fluoroscopy time was markedly shorter and total DAP and ED
were significantly lower in the fluoroscopy-free group (Group 1)
compared with the standard group (Group 2). Total procedure
time did not differ significantly between the groups. A between
group comparison including the time needed to acquire the map of
the left atrium as described above, the time required to perform
the ablation (ablation time), and the net duration of radiofrequency
energy delivery (net RF time) in the groups is given in Table 2.
Secondary outcomemeasures
The procedural endpoint of PVI was reached in all patients. No
complicationsoccurred in the twogroups.Acute radiationdermatitis
occurred in none of the patients.
Success rates were similar between the two groups. In the
fluoroscopy-free group (Group 1) and in the standard group
(Group 2), respectively, 22 of 30 patients (73%) and 21 of 30 patients
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4.2 (2.6–5.6) 9.3 (6.4–13.9) ,0.001
Total DAP
(Gy×cm2)
13.2 (6.2–22.2) 17.5 (11.7–29.7) 0.036
Effective dose (mSv) 2.65 (1.25–4.43) 3.49 (2.33–5.94) 0.036
Procedure time (min) 133+37 134+37 0.884
Mapping time (min) 18+6 17+10 0.951
Ablation time (min) 80+26 86+35 0.409
Net RF time (s) 1765+719 2040+861 0.185
All values are given as mean+ 1 standard deviation or median (IQR).
Conversion factor for ED (mSv) ¼ DAP (Gy × cm2) × 0.2 (mSv/Gy × cm2).8
Mapping time: time fromthebeginningof themappingof the left atriumto the startof
the ablation. Ablation time: time from the start of the first ablation to the end of the
procedure. Net RF time: duration of radiofrequency energy delivery.
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Age (years) 60+10 59+11 0.648
Weight (kg) 84+16 84+13 0.973
Height (cm) 175+8 176+9 0.543
BMI (kg/m2) 28+5 27+3 0.633
Sex: Male 22 (73) 22 (73) 1.000
Duration of AF (months) 29 (7–99) 33 (12–56) 0.755
Left atrial size (mm) 43+8 40+7 0.231
Left ventricular ejection
fraction (%)
58 (45–60) 57 (53–60) 0.811
No structural heart disease 24 (80) 23 (77) 1.000
HCVD 6 (20) 6 (20) 1.000
CAD 3 (10) 0 (0) 0.237
All values are given as n (%) for categorical and median (IQR) or mean+ standard
deviation for continuous variables.
AF, atrial fibrillation; CAD, coronary artery disease; HCVD, hypertensive
cardiovascular disease.
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(70%) did not have any recurrence of AF during a follow-up of 12
months (P . 0.99). A contact force-sensing catheter was used in
18 of the 30 patients (60%) in Group 1 and in 12 of 30 patients
(40%) in Group 2 (P ¼ 0.196). No statistical difference in procedural
parameters, safety, and outcome between procedures performed
with and without force-sensing catheters could be observed.
Discussion
Main findings
The main findings of this study are (i) Performing mapping and abla-
tion during PVI without using fluoroscopy after transseptal puncture
is feasible in 97% of patients undergoing AF ablation. This is the case
without additional technical equipment such as intracardiac or trans-
esophageal echocardiography. (ii) Adopting a procedural protocol
with the aim of avoiding fluoroscopy after transseptal puncture by
using routinely available features of a latest generation EAM system
(Carto3) results in a marked decrease in fluoroscopy time, total
DAP and ED compared with PVI procedures using the same
mapping system but no specific recommendation regarding fluoros-
copy. (iii) Mapping and ablation time and overall procedure duration
wasnot longerwhenusing thenon-fluoroscopic approachcompared
to the standard approach. (iv) Outcome and complication rates did
not differ between the groups.
Impact of novel technological developments
Electroanatomic-mapping systems10 and other technological devel-
opments such as the MediGuideTM system (St. Jude Medical)11 or
remote magnetic navigation systems12 have been introduced also
with the intention to reduce radiation burden. In our study, fluoros-
copy duration could be decreased to ,5 min by the development
and implementation of a standardized procedural workflow relying
on non-fluoroscopic guidance as much as possible as recommended
by Heidbuchel et al.8 In our protocol, this included the precise de-
scription of the mapping workflow, the marking of the transseptal
access site and the usage of additional features of the mapping
system such as the electrode markings to determine sheath position
and the two-ring catheter projection or the contact force informa-
tion (Figure 1D). A contact force-sensing catheter was used overall
in 50% of cases. Despite being considered useful, contact force
information was not considered mandatory for a safe and successful
procedure.
Reduction of radiation exposure
The main goal of adopting a protocol of fluoroscopy-free mapping
and ablation is to reduce total DAP and ultimately to decrease the
adverse effects of ionizing radiation to the human body. In that
regard, totalDAPandultimately EDare themost important variables.
However, it is valid to compare fluoroscopy duration as ameasure of
the ‘need’ for X-ray verification when analysing the impact of a
new procedural protocol, especially because, in contrast, total
DAP is dependent on a plethora of variables including the use of
cine acquisitions, the type and configuration of the X-ray system
used, operator training (collimation, less-irradiating angulations),
and patient characteristics.13,14
Perisinakis et al. estimated the average excess of fatal cancers to be
0.05% for patients undergoing ablation procedures with 60 min of
fluoroscopy time.3 However, although a significant reduction inDAP
was achieved with our protocol, the question whether this has a
measurable clinical impact with regard to the occurrence of cancer
remains unknown. Acute adverse effects of radiation (acute radiation
dermatitis) havebeendescribed afterelectrophysiologic procedures,
but were not seen in any patient in this study.15 Therewere no differ-
ences in success rates (freedom from AF during follow-up) between
the groups, but thiswould not be expected since the procedural end-
point was the same in both groups.
Two previous studies have reported PVI without using any fluor-
oscopy.16,17 Intracardiac ultrasound is routinely used in many institu-
tions especially in the United States and was used in both previous
studies to guide the procedure. In most European centres,
however, intracardiac ultrasound is not used to guide PVI. It was
the explicit aim of our study to perform mapping and ablation
without fluoroscopy, but without using intracardiac (or transeso-
pheageal) echocardiography in order not to increase the complexity
of the procedure due to additional technology. The increased com-
plexity is probably reflected in the longer procedure times of 3.5
and 4 h in the two previous studies.16,17 In our study, procedure
times were 130–140 min and there was no difference between
the fluoroscopy-free group and the standard group.
Potential benefits for theoperatorand staff
Reducing radiation exposure has a different implication when focus-
ing on the operator and staff because exposure is long-term and
lead aprons do not protect the whole body. Full-body protection
has become available for physicians with the advent of radiation
protection cabins. However, for the laboratory staff, no such phys-
ical protection is available. Apart from the potential reduction of
malignancies and radiation cataracts, indirect consequences of radi-
ation exposure are the relatively frequent orthopaedic problems
associated with wearing protective apparel.18,19 In our study, the
operator and staff did not wear lead during mapping and ablation,
but the effect on orthopaedic problems was not studied in this
analysis.
Risks of fluoroscopy-free mapping
and ablation
The circumferential-mapping catheter (LassoNav, BiosenseWebster,
Diamond Bar, CA,USA) is usually not visualizedwith the typical Lasso
appearance upon entry into the left atrium. Therefore, it is of utmost
importance to observe the intracardiac electrocardiograms to
prevent the catheter from advancing into the left ventricle and ultim-
ately to prevent entrapment in the mitral valve apparatus. By rotating
the transseptal sheath posteriorly, observing the electrograms, the
EAM information and by decreasing the radius of the adjustable
circumferential-mapping catheter when exiting the sheath in the left
atrium, avoiding the region of the mitral valve was possible in all
cases without any inadvertent positioning or entrapment of the
circumferential-mapping catheter in the mitral valve apparatus.
Furthermore, the region of the mitral annulus was mapped using the
ablation catheter.
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Limitations
This is a non-randomized studyperformedat a single center.Definitive
conclusions about the safety of the fluoroscopy-free approach cannot
bedrawnbasedon the results of this study becauseof the small sample
size. Although no differences were seen in this study, it is conceivable
that outcomes or complication rates differ between the two
approaches when larger samples are studied. Finally, it has to be
noted that the described protocol including a pre-procedural MRI
may not be recommended in patients with pacemakers and ICDs.
Conclusion
Performing mapping and ablation guided by an EAM system without
using fluoroscopy after transseptal puncture is feasible in the vastma-
jority of patients undergoing PVI and is associated with markedly
decreased total fluoroscopy duration and DAP. This approach may
be important especially for younger patients with a higher life-time
risk of radiation-induced neoplasms.
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